Stock Evaluator: Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics Inc. MNPR

$70.29 -0.46 -0.65%
November 19, 2026 4:00:01 PM EST November 10, 2021 Volume: 121,438
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Commentary & Analysis


Financial Summary

Share Statistics MNPR Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $476.3 $212.8 38%
Shares Out (Mil) 8.6 55.2 19%
Institutional Ownership 91.9% 93.3% 60%
Float (Mil) 4.5 40.8 11%
Beta 1.61 1.03 85%
Avg Daily Volume (000s) 153 559 41%
Price Change
(52-week)
(12.8%) 40.3% 42%
Growth MNPR Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (16.8%) (10.5%) 23%
EPS (5yr) 8.4% 15.4% 45
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 6.1% (15.7%) 68%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 9 8 8
Current EPS ($0.873) ($2.843) ($2.785)
Month Ago EPS ($1.135) ($3.041) ($1.916)
# Rev Up 1 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($1.092) ($3.006) ($1.980)
Year/Year Chg 20.6% 53.6% 96.2%
Financials MNPR Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $40 na
Net Income (TTM) (Mil) ($21) ($44) 23%
EPS (TTM) ($2.412) ($1.400) 13%
Operating Cash Flow (TTM) (Mil) ($16) ($34) 16%
Net Cash Flow (TTM) (Mil) ($75) $-0 18%
Long-Term Debt (Q1) (Mil) $0 $4 12%
Enterprise Value (Q1) (Mil) $359 $142 32%
Valuation MNPR Industry
Median
Percentile
(All Stocks)
P/B 3.74 1.97 75%
P/E na 16.8 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.8 na
Ratios MNPR Industry
Median
Percentile
(All Stocks)
Gross Margin na 67.6% na
Net Margin na (50.8%) na
ROA (15.0%) (47.4%) 22%
ROE (15.3%) (51.4%) 25%
Liabilities to Assets 2.4% 29.6% 1%
F-Score 3 3 18%

Monopar Therapeutics Inc. did not pass any screens on 11/19/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors